Sacituzumab govitecan

Drug Profile

Sacituzumab govitecan

Alternative Names: hRS7-SN38 antibody drug conjugate; IMMU-132; Isactuzumab govitecan; TROP-2-SN-38

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators; TROP2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Solid tumours
  • Preclinical Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 11 Sep 2017 Updated interim efficacy and adverse events data from a phase II trial in Solid tumours presented at the European Society for Medical Oncology (ESMO-2017) Congress
  • 16 Aug 2017 Immunomedics plans a phase III trial for Breast cancer in early fourth quarter of 2017
  • 10 Jul 2017 Adverse events and efficacy data from a phase II trial in Solid tumours released by Immunomedics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top